Survodutide (BI 456906) – 10MG per vial

Clinical Test Expectation – Survodutide – 10mg – Human Subjects : Reduced appetite and slower digestion. Significant weight loss. Increased fat burning and improved metabolism. Signs it could help improve liver health in people with MASH (metabolic dysfunction-associated steatohepatitis). Improvements in blood sugar regulation
Strength – 10mg per vial

Detailed Product Information
Survodutide is an innovative injectable therapy currently undergoing clinical trials for the treatment of obesity and fatty liver disease (MASH). It functions by targeting both GLP-1 and glucagon receptors, which aids in appetite reduction, fat burning, and metabolic enhancement. Preliminary studies indicate that it may promote liver health in addition to facilitating weight loss. Initial findings suggest that this treatment could not only assist in weight reduction but also serve as an effective intervention for fatty liver disease.

Survodutide is classified as a dual agonist medication that activates both GLP-1 and glucagon receptors. These hormones, which occur naturally in the body, are essential for regulating appetite, blood sugar levels, and metabolism.

Other weight management drugs that focus on GLP-1 receptors, such as Wegovy (Semaglutide), primarily function by diminishing appetite and slowing digestion, thereby prolonging the sensation of fullness. Survodutide shares this mechanism but extends its effects by simultaneously activating glucagon receptors.

Glucagon plays a crucial role in the breakdown of fat and the enhancement of energy levels. By stimulating both GLP-1 and glucagon receptors, Survodutide has the potential to reduce hunger while simultaneously increasing fat burning efficiency. This dual-action approach may yield benefits that combine weight loss with various metabolic improvements, including support for individuals with fatty liver disease.

MASH, formerly referred to as non-alcoholic steatohepatitis, is a chronic and progressive liver disease. It results from an accumulation of fat in the liver, which leads to inflammation and long-term damage, including tissue scarring known as fibrosis. This condition is commonly found in individuals who are overweight or have insulin resistance.

The GLP-1 agonist aids in reducing appetite and enhancing the sensation of fullness, while the glucagon agonist present in Survodutide directly affects the liver. In a phase 2 clinical trial involving patients diagnosed with MASH, 83% exhibited signs of improved liver health after 48 weeks of treatment with Survodutide.

This development is particularly encouraging, especially considering that approximately 34% of individuals with obesity are also affected by MASH, a condition that currently lacks any approved treatment options.

What are the side effects of Survodutide?
Similar to other weight loss injectables, the most common side effects reported in clinical trials were gastrointestinal in nature: Nausea, Vomiting, Constipation, Diarrhoea

The most adverse reactions are thought to have occurred at higher doses. Like with other injectable weight loss medications, it’s important to start on a low dose and increase gradually under medical supervision.

Dosing Details – Please visit this link for Dosing instructions : https://researchpeptides.co.za/dosage-instructions/